Drugs / autologous T cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05732948 | Aug 2018 → Dec 2024 | prostate cancer | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT02277392 | Sep 2014 → Jun 2015 | uterine adnexa cancer | Abramson Cancer Center at Penn Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT01355965 | May 2011 → Jul 2015 | malignant pleural mesothelioma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT01312376 | Mar 2011 → Oct 2015 | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00603460 Comparator | Jan 2012 → Jan 2013 | ovarian cancer, primary peritoneal carcinoma | University of Pennsylvania | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous T cells | “All subjects will receive a single intravenous infusion of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T-cells at the starting dose of 10-15 x 109...” NCT01312376 ↗4“adoptive transfer of vaccine-primed, ex vivo CD3/CD28-costimulated peripheral blood autologous T-cells, and recombinant human interleukin-18 (SB-485232, IL-18) treatment” NCT02277392 ↗ “adoptive transfer of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells” NCT00603460 ↗ |
| Known as | CIR T cells | “The purpose of this study is to test the safety of infusing the study product CIR T cells.” NCT01355965 ↗ |
| Action | Deplete | “This is a phase I study which will test the safety of different doses of the patients own immune cells which have been changed to help recognize and destroy the cancer cells.” NCT05732948 ↗ |
| Modality | Cell therapy | “adoptive transfer of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells” NCT00603460 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT01312376 ↗ |
| Target | PSCA | “PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T” NCT05732948 ↗ |